Related Experiment Video
Updated: Mar 16, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Antioxidative Theranostic Iron Oxide Nanoparticles toward Brain Tumors Imaging and ROS Production
Sophie Richard1, Ana Saric2,3, Marianne Boucher4
1Laboratoire CSPBAT, CNRS UMR 7244 UFR SMBH, Université Paris 13 Sorbonne Paris Cité, F-93017 Bobigny, France.
Abstract:
Gliomas are the most common primary brain tumor in humans. To date, the only treatment of care consists of surgical removal of the tumor bulk, irradiation, and chemotherapy, finally resulting in a very poor prognosis due to the lack of efficiency in diagnostics. In this context, nanomedicine combining both diagnostic and magnetic resonance imaging (MRI) and therapeutic applications is a relevant strategy referred to theranostic. Magnetic nanoparticles (NP) are excellent MRI contrast agents because of their large magnetic moment, which induces high transverse relaxivity (r2) characteristic and increased susceptibility effect (T2*). NP can be also used for drug delivery by coating their surface with therapeutic molecules. Preliminary in vitro studies show the high potential of caffeic acid (CA), a natural polyphenol, as a promising anticancer drug due to its antioxidant, anti-inflammatory, and antimetastatic properties. In this study, the antioxidative properties of iron oxide NP functionalized with caffeic acid (γFe2O3@CA NP) are investigated in vitro on U87-MG brain cancer cell lines. After intravenous injection of these NP in mice bearing a U87 glioblastoma, a negative contrast enhancement was specifically observed on 11.7 T MRI images in cancerous tissue, demonstrating a passive targeting of the tumor with these nanoplatforms.
Insights
Iron oxide nanoparticles functionalized with caffeic acid show potential for brain cancer theranostics. These nanoparticles aid in diagnosing gliomas using MRI and offer a novel drug delivery platform for targeted cancer therapy.
Area of Science:
- Nanomedicine
- Biotechnology
- Oncology
Background:
- Gliomas are primary brain tumors with poor prognosis due to diagnostic limitations.
- Current treatments (surgery, radiation, chemotherapy) are insufficient.
- Theranostics, combining diagnostics and therapy, offer a promising strategy.
Purpose of the Study:
- To investigate the theranostic potential of iron oxide nanoparticles functionalized with caffeic acid (γFe2O3@CA NP).
- To evaluate the antioxidative properties of γFe2O3@CA NP in vitro.
- To assess the diagnostic capabilities of γFe2O3@CA NP in vivo using MRI.
Main Methods:
- In vitro studies on U87-MG brain cancer cell lines to assess antioxidative properties.
- In vivo studies involving intravenous injection of γFe2O3@CA NP in mice bearing U87 glioblastoma.
- High-field (11.7 T) MRI to observe contrast enhancement in cancerous tissue.
Main Results:
- γFe2O3@CA NP demonstrated antioxidative properties in vitro.
- Specific negative contrast enhancement was observed in cancerous tissue on MRI images after NP injection.
- These findings indicate passive tumor targeting by the nanoplatforms.
Conclusions:
- γFe2O3@CA NP show potential as theranostic agents for glioma treatment.
- The nanoparticles can serve as effective MRI contrast agents for passive tumor targeting.
- Caffeic acid functionalization enhances the therapeutic potential of iron oxide nanoparticles.
